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Abstract
Purpose The purpose of our study was to investigate the two-
year outcome of Aflibercept treatment for neovascular age-
related macular degeneration (nAMD), using the Observe-
and-Plan regimen, an individually planned treatment regimen,
based on the predictability of an individual’s need for
retreatment, aiming to reduce the clinical burden.
Methods Our prospective study used the Observe-and-Plan
regimen with Aflibercept to treat nAMD: Three loading doses,
followed by monthly observation visits until the disease-
recurrence interval was determined, which then was shortened
by 2 weeks in a treatment plan for the next three injections
without intermediate monitoring visits. The subsequent treat-
ment plans were adjusted according to periodically assessed
disease activity. The primary outcome measures were visual
acuity changes, number of injections, and number of monitor-
ing visits.
Results The study included 112 eyes of 102 patients with a
mean age of 80.7 years (SD 7.6). Mean visual acuity (VA)
improved from 61.8 ETDRS letters (20/60+2) at baseline, by
8.5, 8.0, and 6.2 letters at months 3, 12 and 24, respectively.
Mean central retinal thickness was 438um at baseline, and
reduced by 152um, 155um, and 150um at months 3, 12 and
24, respectively. The mean number of injections was 8.7 and
6.5 in the first and second year, respectively. The mean num-
ber of monitoring visits after baseline was 3.8 and 2.8 during
the first and second year, respectively.
Conclusions The Observe-and-Plan regimen significantly im-
proved VA, while fewer monitoring visits were needed as
compared to other variable dosing regimens, thus reducing
the workload for chronic care management of nAMD.
Keywords Age-related macular degeneration . Aflibercept .
Anti-VEGF . Observe-and-plan regimen . Treat and extend
regimen . Clinical burden . Chronic caremanagement
Introduction
Age-related macular degeneration is a highly frequent macular
pathology. Its natural course used to be the main reason of
irreversible vision loss in individuals aged ≥50 years in indus-
trialized countries. Since the introduction of intravitreal anti-
vascular endothelial growth factor (anti-VEGF) treatment the
proportion of legally blind eyes has been reduced. However,
because monthly retreatment, as investigated by the pivotal
trials for Ranibizumab [1, 2], places a heavy burden on the
health care system and on patients, alternative regimens have
been explored. The generalized reduction of treatment fre-
quency with Ranibizumab to every 3 months resulted in the
loss of initial visual acuity improvement. [3] For the introduc-
tion of Aflibercept, the corresponding pivotal trial investigated
the option of fixed bimonthly retreatment, with success for an
equal visual acuity outcome as with monthly retreatment,
however, with a fluctuating pattern of structural outcome. [4].
The individual need for retreatment is highly variable be-
tween patients. [5] For some, monthly treatment is required,
others do well on 3 monthly retreatment. [6] Generalized




1 Department of Ophthalmology, University of Lausanne, Jules Gonin
Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland
Graefes Arch Clin Exp Ophthalmol (2017) 255:2127–2134
DOI 10.1007/s00417-017-3762-2
undertreatment is the great danger for functional outcome. [7]
However, generalized overtreatment has been related to an
increased risk of atrophic side effects [8, 9], beside the evident
problem of exaggerated health care costs.
An individualized approach appears to be the most appro-
priate strategy, and the most widely used variable dosing reg-
imen are the pro re nata (PRN) [10, 11] and treat and extend
(TER) regimen. [12, 13] Frequent monitoring visits (monthly
in PRN; with each injection in TER) are needed for these
regimens in order to determine the individualized treatment
need. For the health care institution, this remains a heavy
burden due to the high number of patients.
Our group has evaluated the regularity and predictability of
future treatment need in nAMD [14] which allowed for the
development of an individually planned treatment regimen
called Observe-and-Plan, reducing the number of monitoring
visits needed. [15, 16] Given the satisfying results of this
regimen using Ranibizumab, the aim of this study was to
evaluate the results of the Observe-and-Plan regimen using
Aflibercept. Functional results served as clinical validation
of the regimen, but additional key outcomes were the number
of injections and monitoring visits, or in other terms the fac-
tors which influence the work load.
Materials and methods
This prospective study was undertaken in the medical retina
department of a tertiary referral center (University Eye
Hospital Jules Gonin in Lausanne, Switzerland). Informed
consent was obtained from all individual participants included
in the study.
Study design
Our study involved a prospective noncomparative case series
of nAMD patients, treatment naïve at baseline, undergoing
intravitreal anti-VEGF treatment with Aflibercept, according
to the treatment protocol of the Observe-and-Plan regimen.
For 2 years the functional and anatomical results were record-
ed, along with the treatment time points, injection intervals, as
well as the time points of the monitoring visits. The functional
results served as clinical validation of the regimen as com-
pared to the results in the literature of other regimens. The
aim was to measure the number of monitoring visits and in-
jections needed in order to obtain these functional results.
Patient selection
Inclusion criteria were treatment-naïve nAMD with active
subfoveal choroidal neovascularization (CNV) or retinal an-
giomatous proliferation (RAP), best corrected visual acuity
(BCVA) between 20/25 and 20/400, a maximum lesion size
of 12 disc areas and informed consent.
Exclusion criteria were atrophy or fibrosis in the center of
the macula, any other macular pathology which might poten-
tially interfere with the visual outcome, prior macular treat-
ment, and poor image quality.
Clinical investigation
Baseline examination and all monitoring visits included mea-
surement of BCVA on the Early Treatment of Diabetic Study
(ETDRS) chart, slit-lamp examination, measurement of intra-
ocular pressure, dilated fundus examination, spectral domain
optical coherence tomography (SD-OCT) on the Heidelberg
Spectralis (6 mm, 49 lines; Heidelberg Engineering,
Heidelberg, Germany) and fundus autofluorescence
(Spectralis). Additional fluoresceine angiography (Topcon
TRC-501X, Tokyo, Japan; or HRA, Heidelberg Engineering,
Heidelberg, Germany) was performed at baseline, at month 3
and at month 24, completed with indocyanine green angiog-
raphy (same machine) at baseline.
Observe-and-plan regimen
The principles of the Observe-and-Plan regimen are described
in detail in a previous publication. [16] In summary, the reg-
imen starts with treatment initiation, then measures the indi-
vidual injection-recurrence interval, and finally applies a
slightly shorter interval in a planned series of injections with-
out intermediate monitoring visits. Over time, the interval is
adjusted according to the results in periodical monitoring
visits. In more detail, the regimen starts with three loading
doses, followed by an observation period with monthly mon-
itoring visits that allow for determining the injection-
recurrence interval according to structural signs on SD-OCT
examination (intra- or subretinal fluid) and/or fundus (hemor-
rhage). From the moment when disease activity reappears, the
patient is retreated with an individualized but fixed treatment
plan for several injections, which applies a 2 weeks shorter
interval than the measured injection-recurrence interval (min-
imum 1 month, maximum 3 months). During the series of
injections of the treatment plan, the patient is not monitored
with BCVA or OCT, he directly presents to the injection pro-
cedure. Only after three planned injections the patient is seen
in a monitoring visit that allows evaluating the applied interval
and to adjust the subsequent treatment plans step by step,
depending on the presence or absence of disease activity.
However, this adjustment visit was no later than 6 months
after the last monitoring visit, thus the possible treatment plans
were 3 × 1 month, 3 × 1.5 months, 3 × 2 months,
2 × 2.5 months, 2 × 3 months. If still dry after 3 months, the
patient was given the choice of continuing on a 3-month in-
terval, or observation. The latter was performed every
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1.5 months until 6 months after last injection and thereafter
every 2months. In case of recurrence later than 3months since
last injection, the per protocol treatment plan was 2 × 3
months. However, the investigator was encouraged to adjust
to shorter intervals if needed according to his clinical appreci-
ation. A graphical illustration with an example, helping to
understand the regimen logic of observing, planning and
adjusting, is given in Fig. 1. In addition, comprehensive flow
charts have been previously published. [16, 17].
Data analysis
The data from the monitoring visits and injection visits was
collected for the corresponding time points. For statistical pur-
poses, the visual acuity data and the central retinal thickness
data from the SD-OCT were carried forward from last obser-
vation until next visit. This procedure was not repeated after a
last visit in case of study drop-outs.
The main outcome measure was the mean BCVA
change over time with an end point at 12 and 24 months.
Additional visual outcomes were the proportion of eyes
which lost ≥15 letters, which gained ≥0 letters and propor-
tion of eyes which gained ≥15 letters. Further outcomes
included the mean CRT change, treatment intervals during
the first and second year, the number of injections and
monitoring visits over 2 years.
Results
A total of 112 eyes of 102 patients were included. The partic-
ipants had a mean age of 80.7 years (SD 7.6) and included 72
women (70.6%). All patients were Caucasians. Ninety-seven
patients (107 eyes) and 91 patients (99 eyes) completed the 12
and 24 months follow-up, respectively. Of the 11 patients that
dropped out from the study, eight patients were lost from
follow-up, two patients died during the study, and one patient
discontinued following sterile endophthalmitis. Protocol vio-
lations with interrupted follow-up occurred with nine patients
(nine eyes).
Visual acuity outcomes
At baseline, mean best corrected visual acuity (BCVA) as
measured on the ETDRS chart was 61.8 ETDRS letters (SD
15.4), corresponding to a Snellen equivalent of 20/60+2.
Under treatment, visual acuity improved by a mean of 8.5
(SD 9.2), 8.0 (SD 12.0), and 6.2 (SD 14.6) letters at Months 3,
12 and 24, respectively. All of these improvements are statis-
tically significant (P < 0.001, paired t-test). Figure 2 shows the
BCVA results graphically over time, using all half monthly
time points.
Out of the 107 eyes which completed the first 12 months,
the proportion of eyes that gained ≥15 letters, ≥ 0 letters, or
that lost less than 15 letters was 26%, 80%, and 99%,
Fig. 1 Description and illustration of the Observe-and-Plan regimen VA = visual acuity; SD-OCT = spectral domain optical coherence tomography;
m = months
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respectively. At Month 24, the 99 eyes who completed this
timepoint showed the corresponding proportions of 20%,
82%, and 92%, respectively.
Structural outcome
The mean central retinal thickness measurements on SD-OCT
improved from 438 μm (SD 148) at baseline by 152 μm,
154 μm, and 150 μm at Months 3, 12 and 24, respectively
(Fig. 2).
Factors impacting the clinical burden: Monitoring visits
and injection procedures
The number of monitoring visits with ophthalmic examination
after the baseline visit was a mean of 6.6 (SD 1.7) over the 2-
year study duration (Fig. 3), out of which a mean of 3.8 (SD
1.0) monitoring visits were needed during the first year, and
2.9 (SD 1.2) during second year. The mean number of intra-
vitreal injections of Aflibercept over 2 years was 15.3 (SD 5.2)
including the first three loading doses. This divided into a
mean of 8.7 (SD 3.0) and 6.3 (SD 6.2), in the first and second
year, respectively. The distribution of the number of injections
and monitoring visits is shown in Fig. 3. The graph reveals the
shift of monitoring visits to lower numbers.
The mean retreatment interval as determined by the princi-
ples of the Observe-and-Plan regimen was 1.62 months be-
tween Month 3 and 12, and 1.90 months between Month 12
and 24. Table 1 summarizes the treatment intervals into cate-
gories and compares them for the first and second year: Short
intervals up to 1.5 months (high treatment need), middle in-
tervals between 1.5 and 3months, and long treatment intervals
of 3 months and more (low treatment need). The table shows
the comparison between the first and the second year for 102
eyes with sufficient follow-up into year 2 (at least month 18).
It reveals that the majority of eyes (58.8%) remained in their
category, whether in the short interval category (23.5% of all),
middle (21.6%) or long interval category (13.7%). A trend
was found for a change to a category of longer intervals in
the second year (35.3%); however, major changes were very
Fig. 2 Mean visual acuity change and mean central retinal thickness change in study participants treated with intravitreal Aflibercept for neovascular
age-related macular degeneration according to the Observe-and-Plan regimen during 2 years. Error bars represent the standard error
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rare (one single case from short interval to long intervals). On
the other hand, a change into a shorter interval category in the
second year was infrequent, observed in six eyes (5.9%), in-
cluding only one eye with major change. An additional com-
parison was made using the very first and last interval mea-
sured, this is the interval after the loading doses of Aflibercept,
and the interval at Month 24. The results are shown graphi-
cally in Fig. 4. It was found that 59 eyes (58%) remained
within the stability criteria of +/− one step of interval change.
Safety
In two eyes a pigment epithelium tear with major subretinal
hemorrhage was observed. Both eyes showed severe BCVA
loss (−48 letters and −74 ETDRS letters) despite continuation
on monthly treatment.
Two eyes showed a complicated course due to severe in-
traocular inflammation after injection of Aflibercept.
However, the vitreous tap remained sterile in both eyes, and
their visual acuity recovered partially in one case (−16
ETDRS letters) and completely in the second case (+33
letters).
Two cases of death were considered unrelated to the study
or the ocular treatment with Aflibercept.
Study-regimen related complications were not observed.
However, in two patients (two eyes) the investigator decided
to apply shorter intervals than normally required by the pro-
tocol, due to clinical impression of significant recurrence. In
both eyes, visual acuity was well maintained during this re-
currence and thereafter. All observed cases of vision loss >15
letters were attributable to regimen unrelated events such as
fibrosis, atrophy, endophthalmitis, or pigment epithelium tear
(see above).
Fig. 3 Distribution of the number of monitoring visits and the number of injections in patients treated with intravitreal Aflibercept for neovascular age-
related macular degeneration according to the Observe-and-Plan regimen
Table 1 Distribution of first year and second year treatment interval in categories of short, middle, and long treatment intervals according the the
Observe-and-Plan regimen using Aflibercept for neovascular age-related macular degeneration
Treatment interval year 1 Treatment interval year 2 Total
≤ 1.5 months > 1.5 and <3 months ≥ 3 months
≤ 1.5 months N (% within the first year category) 24 (46.2%) 27 (51.9%) 1 (1.9%) 52 (100.0%)
% of all patients 23.5% 26.5% 1.0% 51.0%
> 1.5 and N (% within the first year category) 3 (9.1%) 22 (66.7%) 8 (24.2%) 33 (100.0%)
< 3 months % of all patients 2.9% 21.6% 7.8% 32.4%
≥ 3 months N (% within the first year category) 1 (5.9%) 2 (11.8%) 14 (82.4%) 17 (100.0%)
% of all patients 1.0% 2.0% 13.7% 16.7%
% of all patients 27.5% 50.0% 22.5% 100.0%
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Discussion
Anti-VEGF treatment for nAMD represents a major challenge
for clinical practice due to the high prevalence of the disease,
the chronicity of the repetitive treatment, and the need for
timely retreatment. The retreatment regimen plays an impor-
tant role in order to respond to these challenges, and simulta-
neously adjust the treatment to the individual patient’s need.
Several regimens have been introduced as an alternative to the
fixed monthly or bimonthly retreatment schedule used in the
pivotal trials. [1, 2] During the early years of anti-VEGF treat-
ment, the pro re nata (PRN) regimen, based on monthly visits
and re-injections as soon as signs of reactivation were discov-
ered, [5, 10] was the most commonly adopted regimen in
clinical routine. The downfall of this regimen is the impossi-
bility to plan ahead, and the need for monthly visits. On this
background, the Treat and Extend regimen offers the advan-
tage to anticipate the next injection on an interval based con-
cept, allowing for better ahead planning and a reduced number
of visits. [12] In addition, it appears to better control for recur-
rences. [12] It is nowadays the most widely adopted regimen
[ASRS survey 2015]. Simultaneously with the introduction of
the Treat and Extend regimen, our group investigated the de-
gree of regularity of injection-recurrence intervals. [14] The
results revealed high intraindividual regularity (individual SD
0–2 weeks) and a good predictive value of the first measured
interval after the loading doses (R = 0.70). [14] Based on these
results, the Observe-and-Plan regimen was developed. Its ef-
ficacy and safety was reported, using Ranibizumab as the
drug. [15, 16] The major advantages of the regimen were the
planning ahead for up to 6 months and the reduced number of
monitoring visits. This allowed for better clinical management
of the human and technical resources. [18] The financial out-
come in terms of cost-effectiveness was also reported in the
same study [16], and was not repeated in the present report.
In the present study we intended to validate the Observe-
and-Plan regimen for the use of Aflibercept. In addition, as a
second study using the same regimen, it may serve as confir-
mation of the regimen validation. Truly, a regimen with strong
reduction of the number of monitoring visits needs to demon-
strate its reliability for functional outcomes. The results of this
study revealed indeed a very similar outcome: Visual acuity
was improved and this visual benefit was well maintained
over two years, although with some minor loss over time.
Some of this slow loss was attributable to a case of severe
pigment epithelium rupture and major vision loss, a compli-
cation well known in cases of pigment epithelium detachment,
with or without treatment. [19–21] We consider that the over-
all adequate functional results may serve as clinical validation
of the regimen Observe-and-Plan. In addition, in comparison
with the pivotal trials using Aflibercept for nAMD in a fixed
monthly or bimonthly regimen during the first year, and pro re
nata in the second year (VIEW studies) [22], our results are
well comparable: After one and two years respectively, the
Fig. 4 Distribution of the first
measured interval after loading
doses (horizontal axis), plotted
against the last applied interval at
Month 24 (vertical axis), for eyes
that underwent treatment with
Aflibercept for neovascular age-
related macular degeneration
according to the Observe-and-
Plan regimen. The term
Bobservation^ is equivalent to any
interval longer than 3 months.
These eyes were followed
regularly without planned
injection
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VIEW studies reported a visual improvement of 8.3–9.3 and
6.6–7.6 ETDRS letters as compared to 8.0 and 6.2 ETDRS
letters in our study. However, comparisons between studies
are limited due to different inclusion criteria and methods.
With regard to adequateness of the regimen, the best pos-
sible maintenance of the mean visual acuity change over time
is one of the most important outcome parameters. However,
the concern clinicians may have when using the regimen
Observe-and-Plan is the absence of intermediate monitoring
visits. Some may fear potential undertreatment, resulting re-
currences and subsequent visual loss. In order to address this
question, we chose a double approach, in addition to the over-
all visual acuity results: First, we looked for recurrences which
needed intensive treatment as decided by the investigator. Two
cases were identified. However, there was no associated vi-
sion loss found. Second, we reviewed all cases with vision
loss of >15 letters. In all of these cases, a clinical reason
unrelated to the specific regimen was found (endophthalmitis,
tear of the retinal pigment epithelium), and no case was asso-
ciated with major exudative recurrence. Therefore, we con-
clude that the regimen is safe.
The satisfying functional results of the regimen were obtained
with 15.3 injections over two years. This compares well with
other variable dosing regimen, on the high end. The investigators
actually applied a very strict retreatment policy in case of any
intra- or subretinal fluid based on the very sensitive OCT exam-
ination on the Spectralis OCT, which might have led to early
retreatment.
However, the main interest of the Observe-and-Plan regi-
men is the dramatically lower number of monitoring visits
(3.8 in the first year, 2.9 in the second year) as compared to
other retreatment regimens. The monitoring visits are in our
experience the time consuming part for the health care team.
The traditional variable dosing regimen PRN requires month-
ly monitoring visits. However, in real life the human and tech-
nical resources are frequently a limiting factor for the manage-
ment of the high number of patients needing chronic care.
This might explain some of the suboptimal outcome in real
life reports. [7] In addition, monthly monitoring visits place a
heavy burden on patients as well, potentially inducing com-
pliance problems. The Observe-and-Plan regimen was devel-
oped with the perspective to optimize the number of visits
without neglecting the individual need for treatment. The re-
sults of this study confirm that planning ahead for an individ-
ual’s need for treatment, while skipping monitoring visits, is
possible and allows for good visual results. Thus, the regimen
Observe-and-Plan reduces substantially the need for human
and technical resources (by two thirds in comparison with
the monthly PRN regimen, and approximately half in compar-
ison with treat and extend). In an environment of limited hu-
man resources and/or limited access to the technical instru-
ments such as OCT, this allows for better chronic care man-
agement of neovascular AMD care clinics with the given
limited resources. In addition, patients did appreciate that the
time spent in the clinic was reduced and well planned ahead.
Some limitations of the study need to be acknowledged: First,
the absence of a direct comparison arm does not allow to formal-
ly prove non-inferiority. However, the analysis of BCVA im-
provement and stability over time is an indirect evidence of the
value of the regimen. Second, the number of participating pa-
tients was relatively limited. Third, the number of protocol vio-
lations and the number of patients which were lost to follow-up
were not low and could have influenced the results. However, we
were unable to find a trend for different outcome for these pa-
tients. Fourth, it would have been interesting to compare the
outcome of this study with the previous analog study using
Ranibizumab. Unfortunately, this was not possible. In addition
to the fact that independent studies are never perfectly compara-
ble, the use of different OCT machines and a different team of
investigators make the direct comparison impossible. However,
the results are overall very similar and not suggestive of major
differences. In particular, no sign of lower need for retreatment
with Aflibercept as compared with Ranibizumab was found.
In conclusion, the Observe-and-Plan regimen is a promising
approach in order to treat nAMD eyes with an adequate number
of anti-VEGF injections, individualized according to their need,
yet planned ahead avoiding unnecessary monitoring visits. This
allows for good visual outcome, with the usual mean number of
injections, but with the major advantage of lower need for re-
sources due to dramatically reduced number of monitoring visits.
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